UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 7,437.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 92,257 shares of the company's stock after acquiring an additional 91,033 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.18% of Immunocore worth $2,872,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of IMCR. Primecap Management Co. CA lifted its holdings in Immunocore by 26.7% during the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company's stock worth $76,954,000 after acquiring an additional 520,950 shares in the last quarter. Candriam S.C.A. raised its stake in Immunocore by 65.8% in the 2nd quarter. Candriam S.C.A. now owns 313,423 shares of the company's stock valued at $10,621,000 after acquiring an additional 124,417 shares during the period. Frazier Life Sciences Management L.P. bought a new stake in shares of Immunocore during the 2nd quarter worth about $3,686,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Immunocore by 16.2% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 397,463 shares of the company's stock worth $13,470,000 after acquiring an additional 55,463 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Immunocore by 14.5% during the second quarter. Renaissance Technologies LLC now owns 646,920 shares of the company's stock worth $21,924,000 after buying an additional 82,120 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.
Immunocore Price Performance
NASDAQ:IMCR traded down $1.40 during mid-day trading on Friday, reaching $28.91. The stock had a trading volume of 649,506 shares, compared to its average volume of 498,066. The stock has a market capitalization of $1.45 billion, a P/E ratio of -30.43 and a beta of 0.73. Immunocore Holdings plc has a one year low of $28.27 and a one year high of $76.98. The firm has a 50 day moving average price of $32.28 and a two-hundred day moving average price of $35.28. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.
Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business had revenue of $80.25 million during the quarter, compared to the consensus estimate of $78.94 million. During the same period in the previous year, the firm posted ($0.59) earnings per share. The firm's revenue for the quarter was up 23.7% on a year-over-year basis. As a group, analysts expect that Immunocore Holdings plc will post -0.94 earnings per share for the current year.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on IMCR shares. Guggenheim lowered Immunocore from a "buy" rating to a "neutral" rating in a report on Monday, October 7th. HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research report on Thursday, October 24th. Morgan Stanley reaffirmed an "equal weight" rating and set a $35.00 price target (down previously from $74.00) on shares of Immunocore in a research note on Friday. Needham & Company LLC lowered their price target on shares of Immunocore from $78.00 to $71.00 and set a "buy" rating for the company in a report on Thursday, November 7th. Finally, UBS Group assumed coverage on Immunocore in a research note on Thursday, October 24th. They issued a "sell" rating and a $24.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, Immunocore has a consensus rating of "Moderate Buy" and an average target price of $65.64.
Read Our Latest Stock Analysis on Immunocore
About Immunocore
(
Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Recommended Stories
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
